Atreca is developing antibody-based therapeutics that initiate, shape, and extend the anti-tumor immune response in cancer patients.
The overarching goal of cancer immunotherapy is to drive an “autoimmune attack” by a patient’s own immune system against tumor tissue—to destroy a tissue that the patient does not want. Armed with this insight that successful outcomes in cancer immunotherapy rely upon mechanisms similar to those driving deleterious autoimmune disease, Atreca is developing immuno-oncology therapeutics that induce the immune system to target tumor tissue.
Atreca’s Immune Repertoire Capture® technology uniquely enables an industrialized approach to generating such therapeutics, via analyzing the clinically relevant, active B cell responses of patients whose immune systems are indeed targeting tumor tissue.
Atreca is developing a portfolio of antibody therapeutics that drive tumor-targeting by the immune system in multiple indications, in large subgroups of patients, as monotherapy and in combination with other immuno-oncology agents.
Please contact us to learn more about Atreca.